Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.55 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | RAB9A | P51151 | 5/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | MEN1 | O00255 | 6/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30610021 | 1.00 | TOP1 (0.56) | TOP1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL42727 | 0.85 | TOP1 (0.53) | TOP1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL9663235 | 0.84 | TDP1 (0.44) | TOP1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL261809 | 0.83 | TDP1 (0.48) | TOP1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL31228169 | 0.83 | TDP1 (0.48) | TOP1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL8948094 | 0.83 | TDP1 (0.48) | TOP1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL8996379 | 0.81 | KDM4E (0.56) | TOP1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL9139505 | 0.80 | ALDH1A1 (0.63) | TOP1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5837067 | 0.80 | PIM1 (0.40) | TOP1ALDH1A1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL9139498 | 0.80 | ALDH1A1 (0.63) | TOP1ALDH1A1MAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4206205-B1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE BEIJING CO LTD (CN) | 2026-03-04 | — | — | EP | claimed |
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE (BEIJING) CO., LTD. (CN) | 2023-09-28 | — | — | US | claimed |
| EP-4206205-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | Primegene (Beijing) Co., Ltd. (CN) | 2023-07-05 | — | — | EP | claimed |
| WO-2022042577-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | 北京普祺医药科技有限公司 | 2022-03-03 | — | — | WO | claimed |
| CN-114085224-A | Preparation method of pyrrolopyrimidine compound | 北京普祺医药科技有限公司 | 2022-02-25 | — | — | CN | claimed |
| EP-4206205-B1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | PRIMEGENE BEIJING CO LTD (CN) | 2026-03-04 | — | — | EP | disclosed |
| CN-120202243-A | Thermosetting resin composition, cured film, substrate, and electronic component | 捷恩智株式会社 | 2025-06-24 | — | — | CN | disclosed |
| US-20250154130-A1 | NOVEL THR BETA ANALOGS AND USES THEREOF | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2025-05-15 | — | — | US | disclosed |
| EP-4476209-A1 | THR BETA ANALOGS AND USES THEREOF | Madrigal Pharmaceuticals, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| CN-119137113-A | THR beta analogues and uses thereof | 马德里加尔制药公司 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024150597-A1 | THERMOSETTING RESIN COMPOSITION, CURED FILM, SUBSTRATE, AND ELECTRONIC COMPONENT | JNC株式会社 | 2024-07-18 | — | — | WO | disclosed |
| WO-2023199238-A1 | NOVEL COMPOUNDS TO TREAT CYTOKINE RELATED DISORDERS | ZYDUS LIFESCIENCES LIMITED (IN) | 2023-10-19 | — | — | WO | disclosed |
| EP-0276436-A1 | Phosphinic acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1988-08-03 | — | — | EP | disclosed |
| US-4673668-A | ANTICANCER AGENTS | SUMITOMO PHARMACEUTICALS COMPANY (JP) | 1987-06-16 | — | — | US | disclosed |
| EP-0107486-B1 | AMINONAPHTHACENE DERIVATIVES AND THEIR PRODUCTION | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1987-04-29 | — | — | EP | disclosed |
| EP-0107486-A1 | Aminonaphthacene derivatives and their production | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1984-05-02 | — | — | EP | disclosed |
| US-4298530-A | FROM PHTHALIC ANHYDRIDE AND MALONIC ACID IN A SOLVENT AND IN THE PRESENCE OF A METAL COMPOUND CATALYST | SHOWA DENKO K.K. (JP) | 1981-11-03 | — | — | US | disclosed |
| US-4250007-A | Photocurable acrylic phosphate esters of epoxidized polybutadiene | UBE INDUSTRIES, LTD. (JP) | 1981-02-10 | — | — | US | disclosed |
| US-4147706-A | Intermediates for polycyclic quinonoid antibiotics | RESEARCH CORPORATION (US) | 1979-04-03 | — | — | US | disclosed |
| US-4070382-A | DAUNOMYCINS, ANTITUMOR AGENTS | RESEARCH CORPORATION (US) | 1978-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303578-A1 | PREPARATION METHOD FOR PYRROLOPYRIMIDINE COMPOUND | DPYD, RPLP2, DHPS | TOP1 1163/4885ALDH1A1 1717/4885MAPT 3577/4885 |
| US-20250154130-A1 | NOVEL THR BETA ANALOGS AND USES THEREOF | THRB, THRA, TSHR | TOP1 4813/4885ALDH1A1 2389/4885MAPT 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.